LTX(N4C), Agonist of ADGRL1, CAS No.rp174471, Agonist of ADGRL1

CAS: rp174471 Cat. No.: rp174471

GRADE & PURITY Moligand™

Specifications

Product Name

LTX(N4C), Agonist of ADGRL1, CAS No.rp174471

Synonymes

latrotoxin(N4C)

Grade

Moligand™

Spécifications et pureté

Moligand™

Type d'action

AGONIST

Mécanisme d'action

Agonist of ADGRL1

CAS

rp174471

Type de molécule

Peptide

Product Line

biological_products

Stockage et expédition

Conditions de stockage de stockage

Room temperature

Cibles associées (humaines)

ADGRL1 Tbio Adhesion G protein-coupled receptor L1 (0 Activities)

Discover Target: ADGRL1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Informations génétiques

• Alternate Names: latrotoxin(N4C)
• Reference:
  • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
  • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
  • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
  • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
  • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
  • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
  • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
  • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
  • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
  • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more
  • 11. Toward a confocal subcellular atlas of the human proteome., Molecular & cellular proteomics : MCP, Barbe, Laurent L and 10 more authors.
  • 12. Kinetic properties of polymorphic variants and pathogenic mutants in human cystathionine gamma-lyase., Biochemistry, Zhu, Weidong W, Lin, Alexander A and Banerjee, Ruma R.
  • 13. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway., Carcinogenesis, Hosgood, H Dean HD and 12 more authors.
  • 14. Relationship between cystathionine gamma-lyase gene polymorphism and essential hypertension in Northern Chinese Han population., Chinese medical journal, Li, Yun Y and 8 more authors.
  • 15. Active cystathionine beta-synthase can be expressed in heme-free systems in the presence of metal-substituted porphyrins or a chemical chaperone., The Journal of biological chemistry, Majtan, Tomas T, Singh, Laishram R LR, Wang, Liqun L, Kruger, Warren D WD and Kraus, Jan P JP.
  • 16. MALDI-TOF MS genotyping of polymorphisms related to 1-carbon metabolism using common and mass-modified terminators., Clinical chemistry, Meyer, Klaus K, Fredriksen, Ase A and Ueland, Per Magne PM.
  • 17. Structural basis for the inhibition mechanism of human cystathionine gamma-lyase, an enzyme responsible for the production of H(2)S., The Journal of biological chemistry, Sun, Qingxiang Q and 10 more authors.
  • 18. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study., Genetic epidemiology, Boyles, Abee L AL and 16 more authors.
  • 19. Large-scale proteomics and phosphoproteomics of urinary exosomes., Journal of the American Society of Nephrology : JASN, Gonzales, Patricia A PA and 7 more authors.
  • 20. An association study of 45 folate-related genes in spina bifida: Involvement of cubilin (CUBN) and tRNA aspartic acid methyltransferase 1 (TRDMT1)., Birth defects research. Part A, Clinical and molecular teratology, Franke, Barbara B and 7 more authors.
  • 21. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China., Environmental and molecular mutagenesis, Shen, Min M and 12 more authors.
  • 22. H2S biogenesis by human cystathionine gamma-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia., The Journal of biological chemistry, Chiku, Taurai T and 5 more authors.
  • 23. Variations in folate pathway genes are associated with unexplained female infertility., Fertility and sterility, Altmäe, Signe S and 7 more authors.
  • 24. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation., World journal of gastroenterology, Renga, Barbara B, Mencarelli, Andrea A, Migliorati, Marco M, Distrutti, Eleonora E and Fiorucci, Stefano S.
  • 25. Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies., Molecular genetics and metabolism, Kraus, Jan P JP and 14 more authors.
  • 26. Relative contributions of cystathionine beta-synthase and gamma-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions., The Journal of biological chemistry, Singh, Sangita S, Padovani, Dominique D, Leslie, Rachel A RA, Chiku, Taurai T and Banerjee, Ruma R.
  • 27. PTEN identified as important risk factor of chronic obstructive pulmonary disease., Respiratory medicine, Hosgood, H Dean HD, Menashe, Idan I, He, Xingzhou X, Chanock, Stephen S and Lan, Qing Q.
  • 28. Genetic susceptibility to distinct bladder cancer subphenotypes., European urology, Guey, Lin T LT and 18 more authors.
  • 29. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip., American journal of human genetics, Talmud, Philippa J PJ and 38 more authors.
  • 30. Integrative predictive model of coronary artery calcification in atherosclerosis., Circulation, McGeachie, Michael M and 13 more authors.
  • 31. Cystathionine beta-synthase 844Ins68 polymorphism is not associated with the levels of homocysteine and cysteine in an Indian population., Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, Kumar, Jitender J, Garg, Gaurav G, Karthikeyan, Ganesan G and Sengupta, Shantanu S.
  • 32. The expression and activity of cystathionine-γ-lyase and 3-mercaptopyruvate sulfurtransferase in human neoplastic cell lines., Amino acids, Jurkowska, Halina H, Placha, Wojciech W, Nagahara, Noriuki N and Wróbel, Maria M.
  • 33. Ancient origin of the CTH alelle carrying the c.200C>T (p.T67I) variant in patients with cystathioninuria., Clinical genetics, Espinós, C C and 8 more authors.
  • 34. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study., Diabetes care, Bailey, Swneke D SD and 11 more authors.
  • 35. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia., PloS one, Jugessur, Astanand A and 12 more authors.
  • 36. [Expression of cystathionine-γ-lyase/hydrogen sulfide pathway in CVB3-induced myocarditis in mice]., Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, Hua, Wang W and 6 more authors.
  • 37. Folate-metabolizing gene variants and pregnancy outcome of IVF., Reproductive biomedicine online, Laanpere, M M and 5 more authors.
  • 38. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells., The Journal of biological chemistry, Yang, Guangdong G, Pei, Yanxi Y, Teng, Huajian H, Cao, Qiuhui Q and Wang, Rui R.
  • 39. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium., Briefings in bioinformatics, Gaudet, Pascale P, Livstone, Michael S MS, Lewis, Suzanna E SE and Thomas, Paul D PD.
  • 40. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility., PloS one, You, Xing-Ji XJ and 8 more authors.
  • 41. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells., Journal of cellular physiology, Yang, Guangdong G, Pei, Yanxi Y, Cao, Qiuhui Q and Wang, Rui R.
  • 42. H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response., Science signaling, Krishnan, Navasona N, Fu, Cexiong C, Pappin, Darryl J DJ and Tonks, Nicholas K NK.
  • 43. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells., Urology, Guo, Hui H and 5 more authors.
  • 44. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines., Cellular signalling, Yin, Peng P and 12 more authors.
  • 45. H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase., Circulation, Kondo, Kazuhisa K and 14 more authors.
  • 46. Reduced cystathionine γ-lyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator., The American journal of pathology, Cindrova-Davies, Tereza T and 5 more authors.
  • 47. Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia., Circulation, Wang, Keqing K and 14 more authors.
  • 48. Regulation of cystathionine γ-lyase in mammalian cells by hypoxia., Biochemical genetics, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 49. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients., Breast cancer research : BCR, Chung, Suyoun S and 6 more authors.
  • 50. [Cystathionine γ-lyase]., Postepy higieny i medycyny doswiadczalnej (Online), Jurkowska, Halina H, Kaczor-Kamińska, Marta M, Bronowicka-Adamska, Patrycja P and Wróbel, Maria M.
  • 51. Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients., The Journal of biological chemistry, Manna, Prasenjit P, Gungor, Neslihan N, McVie, Robert R and Jain, Sushil K SK.
  • 52. Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells., Mutation research, Pan, Yan Y and 5 more authors.
  • 53. The cystathionine γ-lyase/hydrogen sulfide system maintains cellular glutathione status., The Biochemical journal, Lee, Zheng-Wei ZW, Low, Yi-Lian YL, Huang, Shufen S, Wang, Tianxiao T and Deng, Lih-Wen LW.
  • 54. The binding site for the transcription factor, NF-κB, on the cystathionine γ-lyase promoter is critical for LPS-induced cystathionine γ-lyase expression., International journal of molecular medicine, Wang, Maoxian M, Guo, Zhanyun Z and Wang, Shilong S.
  • 55. Regulation of cystathionine gamma-lyase/H₂S system and its pathological implication., Frontiers in bioscience (Landmark edition), Zhao, Kexin K, Li, Hongzhu H, Li, Shuangshuang S and Yang, Guangdong G.
  • 56. Dysregulation of hydrogen sulphide metabolism impairs oviductal transport of embryos., Nature communications, Ning, Nannan N and 5 more authors.
  • 57. Wnt/β-catenin signaling induces the transcription of cystathionine-γ-lyase, a stimulator of tumor in colon cancer., Cellular signalling, Fan, Kun K and 7 more authors.
  • 58. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression., Antioxidants & redox signaling, Shen, Yaqi Y and 7 more authors.
  • 59. Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression., Pigment cell & melanoma research, Panza, Elisabetta E and 11 more authors.
  • 60. A proteome-scale map of the human interactome network., Cell, Rolland, Thomas T and 69 more authors.
  • 61. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase., Cell cycle (Georgetown, Tex.), Paul, Bindu D BD and Snyder, Solomon H SH.
  • 62. The importance of MTHFR, MTR, MTRR and CSE expression levels in Caucasian women with preeclampsia., European journal of obstetrics, gynecology, and reproductive biology, Seremak-Mrozikiewicz, Agnieszka A and 6 more authors.
  • 63. The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population., Ginekologia polska, Mrozikiewicz, Przemysław M PM and 8 more authors.
  • 64. Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids., American journal of physiology. Heart and circulatory physiology, Renga, Barbara B and 9 more authors.
  • 65. Correlation between the cystathionine-γ-lyase (CES) and the severity of peptic ulcer disease., African health sciences, Chen, Xiong X, Wan, Ying-Chun YC, Guo, Tao T, Xu, Can-Xia CX and Wang, Fen F.
  • 66. MPST but not CSE is the primary regulator of hydrogen sulfide production and function in the coronary artery., American journal of physiology. Heart and circulatory physiology, Kuo, Maggie M MM and 10 more authors.
  • 67. Transcriptional Regulation of Cystathionine-γ-Lyase in Endothelial Cells by NADPH Oxidase 4-Dependent Signaling., The Journal of biological chemistry, Mistry, Rajesh K RK and 8 more authors.
  • 68. LPS Up-Regulates Cystathionine γ -Lyase Gene Expression in Primary Human Macrophages via NF-κB/ERK Pathway., Inflammation & allergy drug targets, Badiei, Alireza A, Gieseg, Steven S, Davies, Sian S, Izani Othman, Mohd M and Bhatia, Madhav M.
  • 69. Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S/CSE Pathway., Radiation research, Pan, Yan Y, Zhou, Cuiping C, Yuan, Dexiao D, Zhang, Jianghong J and Shao, Chunlin C.
  • 70. Cystathionine γ-lyase(CSE)/hydrogen sulfide system is regulated by miR-216a and influences cholesterol efflux in macrophages via the PI3K/AKT/ABCA1 pathway., Biochemical and biophysical research communications, Gong, Duo D and 15 more authors.
  • 71. MicroRNA-186 promotes macrophage lipid accumulation and secretion of pro-inflammatory cytokines by targeting cystathionine γ-lyase in THP-1 macrophages., Atherosclerosis, Yao, Yan Y and 9 more authors.
  • 72. Cystathionine γ-lyase is expressed in human atherosclerotic plaque microvessels and is involved in micro-angiogenesis., Scientific reports, van den Born, J C JC and 5 more authors.
  • 73. Dichotomous effects of isomeric secondary amines containing an aromatic nitrile and nitro group on human aortic smooth muscle cells via inhibition of cystathionine-γ-lyase., Biochimie, Ji, Yajing Y and 6 more authors.
  • 74. Distinctive expression pattern of cystathionine-β-synthase and cystathionine-γ-lyase identifies mesenchymal stromal cells transition to mineralizing osteoblasts., Journal of cellular physiology, Gambari, Laura L and 6 more authors.
  • 75. Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency., Antioxidants & redox signaling, Wang, Peipei P and 6 more authors.
  • 76. Augmented H2S production via cystathionine-beta-synthase upregulation plays a role in pregnancy-associated uterine vasodilation., Biology of reproduction, Sheibani, Lili L and 7 more authors.
  • 77. Total sulfane sulfur bioavailability reflects ethnic and gender disparities in cardiovascular disease., Redox biology, Rajpal, Saurabh S and 12 more authors.
  • 78. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides., Gene, Maruyama, K K and Sugano, S S.

Application Protocols

Validated application data are not provided on the product page.

• Item-specific tested applications and recommended conditions: Not specified for this item; refer to CoA/Spec Sheet.

• General workflow (non-item-specific):

  • Prepare a DMSO stock (sterile-filter if needed for cell assays) and perform a solubility/precipitation check at intended assay concentrations.
  • Run a vehicle control series and include counter-screens for assay interference (e.g., fluorescence quenching, redox cycling, aggregation) as appropriate for the assay format.

Biological Roles

Biological function and target engagement are structure- and scaffold-dependent.

• Item-specific biological roles/targets: Not specified for this item; refer to CoA/Spec Sheet or contact support if available under disclosure agreements.

• General context (non-item-specific):

  • Small molecules in discovery libraries are investigated for modulation of enzymes, receptors, ion channels, or protein–protein interactions.
  • Typical studies include binding assays (biophysical or displacement), enzymatic inhibition/activation, phenotypic screens, and ADME profiling.
  • If this compound is pursued, establish a MoA hypothesis only after orthogonal confirmation (e.g., biochemical potency, target engagement by CETSA/TPP, and chemoproteomics where applicable).

• Caution:

  • Avoid inferring biological activity without validated data. No medical or clinical claims are made; for research use only.

Buffer Applications

This item is a small-molecule library member rather than a buffering reagent.

• Item-specific buffer utility: Not specified for this item; refer to CoA/Spec Sheet.

• Practical note (general):

  • If used in biological assays, choose assay buffers compatible with the compound’s solubility and stability (pH, ionic strength, co-solvent percentage). Validate vehicle controls and precipitation limits.

Green Alternatives

When handling or formulating this small-molecule library member, consider greener choices for common operations (general guidance).

• Solvent choices (general):

  • Prefer water, ethanol, isopropanol, ethyl acetate, or 2-MeTHF over higher-toxicity or persistent solvents where feasible in workups or analytics.
  • For LC, evaluate water–ethanol or water–acetonitrile systems; minimize halogenated solvents unless necessary.

• Operational practices:

  • Scale reactions and assays appropriately to minimize waste.
  • Use energy-efficient temperatures (ambient where possible) and microplate formats for screening to reduce solvent volumes.

• Trade-offs:

  • High-solubility vehicles like DMSO are often necessary but should be minimized in final assay conditions; validate that alternative vehicles do not compromise assay signal or compound stability.

• Note:

  • Specific greener synthesis routes cannot be advised without structural information for LTX(N4C).

Pharmaceutical Uses

This catalog item is supplied for research use only and is not intended for human or veterinary use.

• Item-specific pharmacopeial/excipient status: Not specified for this item; refer to CoA/Spec Sheet.

• General R&D context (non-item-specific):

  • Small molecules are sometimes used as analytical reference materials or screening hits during early discovery. If later used in development workflows, ensure qualification per internal QA procedures (identity, purity, stability indicating methods). No therapeutic claims are made or implied.

Physical Properties

Overview of physical constants and handling-relevant metrics.

• Item-specific (from Product Data):

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Storage conditions: Room temperature.

• Physical constants (literature/computed):

  • Boiling point, melting point, density, refractive index, logP/logD, pKa, UV cutoff, solubility: Not specified for this item; refer to CoA/Spec Sheet.

• General chemistry guidance (non-item-specific):

  • For small-molecule library members, initial solubility screening is commonly performed in DMSO (analytical grade, water ≤0.1%) at 10–50 mM, then diluted into assay buffer while monitoring precipitation.
  • If hygroscopicity or polymorphism is a concern, confirm by Karl Fischer and PXRD/DSC as applicable (general guidance).

Quality and Grades

Interpretation of the listed grade and what to verify for this catalog item.

• Item-specific (from Product Data):

  • Grade/Purity: Moligand™ (no numeric purity specified). Exact QC attributes: Not specified for this item; refer to CoA/Spec Sheet.

• What Moligand™ typically implies (general description, not item-specific specifications):

  • A discovery-chemistry focus suitable for ligand screening and SAR exploration.
  • Researchers usually expect identity confirmation (e.g., LC–MS, 1H NMR) and a defined purity assay. For this item, obtain the CoA to confirm analytical methods, acceptance criteria, and any residual solvent or water determinations.

• Stabilizers/inhibitors:

  • None stated for this item. If inhibitors (e.g., BHT) or salts/forms are relevant, they should be disclosed on the CoA; verify prior to use.

• Practical QC checklist (general guidance):

  • Request: batch-specific purity, analytical method, chromatogram, mass spectrum, and water/RS profile if applicable.
  • Verify form (free base/acid vs. salt), counter-ion content, and lot-to-lot consistency for screening campaigns.

Reaction and Applications

This product is listed as part of a small-molecule/compound library with undisclosed structure; synthetic transformations specific to the molecule cannot be recommended without structural data.

• Item-specific applications from catalog: Not provided.

• General research applications (non-item-specific):

  • Use as a test article in biochemical, biophysical, or cell-based screening to probe binding or activity in target classes of interest.
  • Potential roles include SAR seed, tool compound candidate, or counter-screen control in hit triage (subject to structure/quality disclosure under applicable agreements).
  • For analytical characterization, establish reference spectra and retention time under your platform LC–MS/UPLC methods.

• Practical considerations:

  • Confirm identity/purity prior to screening to avoid false positives due to impurities or aggregates.
  • Assess colloidal aggregation (e.g., detergent challenge, DLS) and redox activity (e.g., Amplex Red, HRP-coupled assays) as appropriate.

Reaction Conditions

Reaction parameters are molecule- and functionality-dependent.

• Item-specific conditions: Not specified for this item; refer to CoA/Spec Sheet.

• General guidance for handling small molecules (non-item-specific):

  • Stock solutions: Prepare in dry DMSO at 10–50 mM, store aliquots at room temperature or 4 °C per stability, minimize freeze–thaw.
  • Screening assays: Typical final DMSO ≤0.5–1% v/v; include vehicle controls. Evaluate stability over assay window (e.g., 4–48 h) by LC–MS.
  • If engaging in synthetic modification, choose conditions orthogonal to sensitive motifs once structure is known (avoid strong acids/bases, high temperatures until stability is verified).

Safety and Handling

Safety profile should be confirmed from the product-specific SDS.

• Item-specific hazard information (from Product Data):

  • Signal word: Not specified for this item; refer to SDS.
  • H-statements: Not specified for this item; refer to SDS.
  • GHS classification/pictograms: Not specified for this item; refer to SDS.

• General laboratory precautions (general guidance):

  • Handle in a fume hood with appropriate PPE: lab coat, safety glasses, and chemical-resistant gloves (e.g., nitrile).
  • Avoid inhalation, ingestion, and skin/eye contact. Prevent aerosol formation when weighing or reconstituting.
  • Incompatibilities and reactivity are structure-dependent; keep away from strong oxidizers/reductants and ignition sources until specific data are known.
  • First aid (overview; defer to SDS): in case of skin/eye contact, rinse with water for ≥15 min; if inhaled, move to fresh air; seek medical advice if symptoms persist.
  • Spill response: contain, absorb with inert material, collect as hazardous waste. Decontaminate surfaces per institutional SOPs.

• Waste disposal (general):

  • Dispose via licensed chemical waste streams in accordance with local regulations; do not discharge to drains.

Solvent Selection

Choosing solvents for dissolution and use in assays when the structure is undisclosed.

• Item-specific: No solvent recommendations are specified for this item; refer to CoA/Spec Sheet.

• General strategy (for small-molecule screening compounds):

  • Primary stock: DMSO is commonly used due to broad solvency and assay compatibility at ≤0.5–1% v/v final.
  • Alternatives: DMF or ethanol for stocks when DMSO is unsuitable; ensure assay compatibility and evaluate vehicle controls.
  • Aqueous work: Solubilize in DMSO, then dilute into buffered media with surfactant (e.g., 0.01–0.05% Tween-20 or Pluronic F-127) if precipitation occurs (general guidance).
  • Volatile solvents (acetonitrile, methanol) may aid LC/MS sample prep; confirm stability.

• Practical tips:

  • Perform a mini solubility screen across DMSO, DMF, MeOH, ACN, PBS (with/without surfactant), at room temperature and 37 °C.
  • Check for adsorption to plastics at low micromolar levels; pre-rinse or use low-binding labware.

Storage and Reconstitution

Guidance for maintaining integrity of a small-molecule library member.

• Item-specific (from Product Data):

  • Storage conditions: Room temperature.
  • Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
  • Form/appearance: Not specified for this item; refer to CoA/Spec Sheet.

• General storage guidance (non-item-specific):

  • Store tightly closed in a dry environment, protected from moisture and excessive light. Use desiccant if appropriate.
  • For hygroscopic or air-sensitive materials (if applicable), handle under inert gas and minimize atmospheric exposure.
  • Prepare concentrated DMSO or solvent stocks in small aliquots to avoid repeated freeze–thaw or evaporation–reconstitution cycles.

• Reconstitution (general):

  • Select solvent based on solubility screening; DMSO is a common first choice. Record exact solvent lot and concentration. If aqueous use is required, dilute into buffer with gentle mixing and monitor for precipitation.

• Stability: Not specified for this item; refer to CoA/Spec Sheet.

• Research use note: For research use only.

Structure and Identity

Concise identity summary for a Moligand-series small-molecule library member with undisclosed structure.

• Item-specific (from Product Data)

  • SKU: rp174471
  • Product name: LTX(N4C)
  • Grade/Purity: Moligand™
  • CAS: rp174471 (internal placeholder)
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES / InChI / InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

• Structural features (descriptive)

  • Not specified for this item; refer to CoA/Spec Sheet.

• Practical note

  • This listing belongs to a small-molecule/compound library category. When structure and stereochemistry are undisclosed in the catalog page, obtain the most recent CoA or Structure Disclosure (if available under MTA/NDA) for exact identifiers before planning experiments.

Synthetic Utility

Without a disclosed structure, specific synthetic roles cannot be assigned.

• Item-specific synthetic function: Not specified for this item; refer to CoA/Spec Sheet.

• General considerations (non-item-specific):

  • If the structure becomes available and contains functional handles (e.g., halides, boronates, amines, acids), typical transformations may include cross-couplings, amide couplings, N-alkylations/acylations, or late-stage diversification.
  • Prior to derivatization, confirm purity and functional group integrity by orthogonal analyses (LC–MS, NMR) and assess protecting-group needs.

Target Specificity

Target/reagent specificity information is not provided for this item.

• Item-specific data: Not specified for this item; refer to CoA/Spec Sheet.

• General note: For library compounds, specificity is established empirically by screening against panels and verified with orthogonal assays; avoid assumptions without data.

Foire aux questions

What are the CAS number, molecular formula and molecular weight?

The CAS Number is rp174471.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.